Lisata Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Lisata Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Lisata Therapeutics: 12 sponsored US clinical trials, none currently recruiting.
Lisata Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Extrahepatic Cholangiocarcinoma, with 1 trials.
Top-decile sponsor footprint
Lisata Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT05712356
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
NCT04990427
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
NCT04614467
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
NCT03508609
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
NCT02691247
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT01875653
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
NCT01508910
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
NCT01495364
ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)
NCT00545610
ACT34-CMI -- Adult Autologous CD34+ Cells
NCT00300053
Vaccine Therapy in Treating Patients With Kidney Cancer
NCT00014131
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
NCT00012064
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
How the Lisata Therapeutics early-phase archive is shaped
12 indexed studies, none listed as recruiting (0% open); 8 completed (67%).
Phase mix: 2 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Extrahepatic Cholangiocarcinoma (1 trial), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Lisata Therapeutics: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Lisata Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Lisata Therapeutics page
12 registered trials is a research-attention snapshot, not an endorsement of Lisata Therapeutics or any single study.
- None of Lisata Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Extrahepatic Cholangiocarcinoma is the condition Lisata Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Extrahepatic Cholangiocarcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lisata Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.